Physician profile
Pavan Chepyala
NPI 1982828133
$1,139.19
in general payments reported to CMS, 2019-2025
12 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $149 · 2021: $17.34 · 2022: $19.00 · 2023: $59.51 · 2024: $286 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526 · Education: $18.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.89 |
| Education | $18.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $395.74 | 2019 | |
| Abbvie INC. | $367.90 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $68.95 | 2024-2025 | |
| Janssen Biotech, INC. | $67.85 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.12 | 2020-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $56.28 | 2020-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $36.52 | 2024 | Dupixent |
| Boston Scientific Corporation | $21.26 | 2024 | Compliance Endokit |
| Celltrion USA INC. | $18.21 | 2024 | Zymfentra |
| Ferring Pharmaceuticals INC. | $17.34 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.79 | 2024 | |
| Pfizer INC. | $15.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Chepyala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.